Sinopharm
🇨🇳China
Clinical Trials
0
Active:0
Completed:0
Trial Phases
0 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
No trials found
News
Chengdu UCELLO Biotech's UC101 Becomes First Allogeneic Universal CAR-T Therapy to Receive FDA IND Approval
Chengdu UCELLO Biotech's CD19-targeted allogeneic universal CAR-T therapy UC101 received FDA IND approval on January 11, 2025, marking a historic milestone as the first such product worldwide.
Sinopharm's Mpox Vaccine Candidate Approved for Clinical Trials in China
Sinopharm's mpox vaccine candidate has been approved by China's drug regulator for clinical trials, joining other domestic candidates.
Sinopharm's Mpox Vaccine Candidate Cleared for Clinical Trials in China
Sinopharm's mpox vaccine candidate, developed by the Shanghai Institute of Biological Products, has been approved for clinical trials in China.